EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Mucosal antibody responses to SARS-CoV-2 booster vaccination and breakthrough infection

Disha Bhavsar iD, Gagandeep Singh, Kaori Sano, Charles Gleason, Komal Srivastava, PARIS Study Group, Juan Manuel Carreno, Viviana Simon, Florian Krammer iD

mBio · 19.12.2023 · 14 (6)

DOI: 10.1128/mbio.02280-23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift mBio, erschienen am 19.12.2023. Verfasst von Disha Bhavsar und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Hauptthemen laut MEDLINE: COVID-19, Antibodies, Viral, SARS-CoV-2, COVID-19 Vaccines. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIAID NIH HHS, Japan Society for the Promotion of Science London (JSPS).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Coronavirus disease 2019 (COVID-19) vaccines have saved millions of lives. However, variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have emerged causing large numbers of breakthrough infections. These developments necessitated the rollout of COVID-19 vaccine booster doses. It has been reported that mucosal antibody levels in the upper respiratory tract, especially for secretory IgA (sIgA), correlate with protection from infection with SARS-CoV-2. However, it is still unclear how high levels of mucosal antibodies can be induced. In this study, we measured serum IgG, saliva IgG, and saliva sIgA responses in individuals who received COVID-19 mRNA booster vaccinations or who experienced breakthrough infections. We found that mRNA booster doses could induce robust serum and saliva IgG responses, especially in individuals who had not experienced infections before, but saliva sIgA responses were weak. In contrast, breakthrough infections in individuals who had received the primary mRNA vaccination series induced robust serum and saliva IgG as well as saliva sIgA responses. Individuals who had received a booster dose and then had a breakthrough infection showed low IgG induction in serum and saliva but still responded with robust saliva sIgA induction. These data suggest that upper respiratory tract exposure to antigen is an efficient way of inducing mucosal sIgA while exposure via intramuscular injection is not. IMPORTANCE Antibodies on mucosal surfaces of the upper respiratory tract have been shown to be important for protection from infection with SARS-CoV-2. Here we investigate the induction of serum IgG, saliva IgG, and saliva sIgA after COVID-19 mRNA booster vaccination or breakthrough infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Antibodies, ViralSARS-CoV-2COVID-19 VaccinesImmunoglobulin GSalivaImmunization, SecondaryImmunity, MucosalHumansAdultMaleFemaleImmunoglobulin A, SecretoryVaccinationMiddle AgedAntibody FormationBreakthrough Infections

Stichwörter der Autor:innen

SARS-CoV-2booster vaccinationbreakthrough infectionmRNA vaccinesIgAsalivaspike

Substanzen

Antibodies, ViralCOVID-19 VaccinesImmunoglobulin GImmunoglobulin A, Secretory

Autor:innen und Institutionen

  • Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • The Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

ORCID-Profile: Disha Bhavsar, Florian Krammer

Förderung

  • NCI NIH HHS
  • NIAID NIH HHS
  • Japan Society for the Promotion of Science London (JSPS)
  • HHS | NIH | National Institute of Allergy and Infectious Diseases
  • HHS | NIH | National Cancer Institute

Zitieren

APA

Bhavsar, D., Singh, G., Sano, K., Gleason, C., Srivastava, K., PARIS Study Group, Carreno, J. M., Simon, V., & Krammer, F. (2023). Mucosal antibody responses to SARS-CoV-2 booster vaccination and breakthrough infection. mBio, 14(6). https://doi.org/10.1128/mbio.02280-23

Vancouver

Bhavsar D, Singh G, Sano K, Gleason C, Srivastava K, PARIS Study Group, et al. Mucosal antibody responses to SARS-CoV-2 booster vaccination and breakthrough infection. mBio. 2023;14(6). doi:10.1128/mbio.02280-23

BibTeX
@article{Bhavsar2023,
  author = {Bhavsar, Disha and Singh, Gagandeep and Sano, Kaori and Gleason, Charles and Srivastava, Komal and PARIS Study Group, PARIS Study Group and Carreno, Juan Manuel and Simon, Viviana and Krammer, Florian},
  title = {Mucosal antibody responses to SARS-CoV-2 booster vaccination and breakthrough infection},
  journal = {mBio},
  year = {2023},
  volume = {14},
  number = {6},
  doi = {10.1128/mbio.02280-23}
}
Kostenlos starten →